Merck Digital Sciences Studio Expands with Second Innovation Class to Advance Biopharma and Digital Health Progress in North America

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Merck recently announced the second cohort of the Merck Digital Sciences Studio (MDSS) in Montreal, Canada. MDSS is a collaborative digital health innovation accelerator dedicated to investing in, supporting and mentoring biopharmaceutical start-ups focused on developing cutting-edge digital technologies including artificial intelligence (AI) solutions. MDSS specifically targets innovations in the areas of preventive health, platforms for biologics research and development (R&D) and 3D translational disease models.

Congratulations to the twelve Canadian and U.S start-ups selected to be part of the second cohort! We are thrilled to see NuvoBio, an OBIO® member, among the selected companies.

Read more
Arsheen Kaur
Previous

Ten National and Regional Ontario Genomics Projects are Part of $20 Million Funding Package
Next

Revolve Surgical Wins FDA Clearance for Surgical Robot